

THORAX

Tous ces essais sont à retrouver sur ACTIS Oncology sur l'application Oncoclic pour un adressage facilité de vos patients, télécharger l'application :



STUDY NAME	PHASE	MOLECULE	COHORT TYPE			PREVIOUS LINE
			COHORT NUMBER	TUMOR TYPE	SPECIFICITY	
AGADIR	II	Atezolizumab + BDB001 + radiothérapie	3	NSCLC	Refractory anti PD-1/L1	
BT-001.01	II	Pembrolizumab IV + TG6030 IT	RDP2	NSCLC	No EGFR, ALK or BRAF positive tumour mutations or ROS1	Anti-PD-1 or anti-PD-L1 agents (documented PD) and one prior systemic treatment including chemotherapy
BT8009	II	BT8009 5 mg/m ²	B6	NSCLC		Recurred after or have been refractory to previous therapy
CFT1946-1101	I/II	CFT1946	Phase 1 (escalade de dose)	NSCLC	BRAFi, platinum-based therapy (if eligible), and an immunotherapy regimen including ICI (in any sequence or in combination)	If the immunotherapy regimen (or the immuno-oncology combination) was given in the neoadjuvant or adjuvant setting, subjects are eligible if they progressed either on treatment or within the 6 months following completion.
D9570C00000	I	AZD7788	Extension B2	NSCLC	B2 : PD-L1 high TPS >=50% IO naïf	no prior therapy including IO therapy
			Extension B4	Advanced or metastatic GC or GEJC	No PD-L1 status requirement but IO acquired resistance = ≥ 6 month of treatment	at least one but no more than two prior lines of systemic therapy in advanced/metastatic setting, of which only one prior line of therapy contained an approved anti-PD-1/PD-L1 therapy
LOXO-RAS-20001	Ib expansion	LY3537982 + pembrolizumab	B8	NSCLC with Brain metastasis	KRAS G12C TUMOR TISSUE OR LIQUID BIOPSY	Patient must have progressed/be intolerant/ineligible for immunotherapy and platinum based therapy No mutation : EGFR, ALK, BRAF (V600), MET (exon 14), ROS1, RET or NTRK 1/2/3
Regomune	II	Regorafenib + Avelumab	H	NSCLC		max 2 prior lines (max 1 line of PD(L)1 mAb and max 1 line of platinum) anti PDL1 mandatory
		Regorafenib + Avelumab	P	Malignant pleural mesothelioma		At least one line and max 1 line of PD(L)1/CTLA-4 mAb (received at least 4 month), anti PDL1 not mandatory



Senology

Tous ces essais sont à retrouver sur ACTIS Oncology sur l'application Oncoclic pour un adressage facilité de vos patients, télécharger l'application :



STUDY NAME	PHASE	MOLECULE	COHORT TYPE			PREVIOUS LINE
			COHORT NUMBER	TUMOR TYPE	SPECIFICITY	
BT-001.01	II	Pembrolizumab IV + TG6030 IT	RDP2	TNBC		At least one systemic treatment (must include an anthracycline and a taxane)
GO39374	I	GDC-0077 + Trastuzumab + Pertuzumab	G	Breast HR+ HER2+		
GO40311	Ib	Runimotamab +/- trastuzumab		Breast HER2+		At least one line
INCB123667-101	I	INCB123667-101	Part 1b Group 4	TNBC	CCNE1 amplification	2 prior lines of chemotherapy max
REGOMUNE	II	Regorafenib + Avelumab	L	TNBC		At least one line and max 1 line of PD(L)1 mAb (received at least 4 month) anti PDL1 mandatory
RLY 2608-101	I	RLY-2608 +/- Fulvestrant	1	Advanced/metastatic breast cancer	PIK3CAmut, HR+, HER2-Escalade de dose	≤1 ligne de chimiothérapie ≥1 inhibiteur des kinases cycline-dépendantes (CDK) 4/6 ≥1 thérapie anti-oestrogène ≥1 inhibiteur PARP en cas de mutation germinale documentée des gènes BRCA1/2
	I	RLY-2608 +/- Fulvestrant	2	group 1a : Advanced/metastatic breast cancer	PIK3CAmut, HR+, HER2-RP2D1 (600mg BID) Expansion	with NO prior PI3K alpha inhibitor RP2D1 (dose recommandé 1)



Thyroid

Tous ces essais sont à retrouver sur ACTIS Oncology sur l'application Oncoclic pour un adressage facilité de vos patients, télécharger l'application :



STUDY NAME	PHASE	MOLECULE	COHORT TYPE			PREVIOUS LINE
			COHORT NUMBER	TUMOR TYPE	SPECIFICITY	
CFT1946	I/II	CFT1946 + Tramétinib	Arm B (CFT1946 + trametinib)	ATC	SoC therapy options per their physician's best judgment	All subjects must have received ≥1 prior line of SoC therapy for their unresectable locally advanced or metastatic disease,

DERMATOLOGY

STUDY NAME	PHASE	MOLECULE	COHORT TYPE			PREVIOUS LINE
			COHORT NUMBER	TUMOR TYPE	SPECIFICITY	
BT-001.01	II	Pembrolizumab IV + TG6030 IT	RDP2	Merkel Cell Carcinoma		One prior line of systemic therapy
			RPD2	Melanoma		Prior treatment with anti-PD-1 or anti-PD-L1 +/- anti-CTLA-4 and BRAF or MEK when appropriate
CFT1946-1101	I/II	CFT1946	Phase 1 (dose escalation)	Melanoma	BRAFi and an immunotherapy regimen including ICI (in any sequence or in combination). <i>NOTE : experimental small molecule checkpoint/BRAF inhibitors given in the context of a clinical trial are acceptable.</i>	
EVICTION-ICT-01-101	I/Ila	ICT01 + Pembrolizumab	G	Melanoma CPI-refractory	Circulating y962 T cell count ≥ 20000 cells/mL Pembro Combo	
IGNYTE (REPLIMUNE)	II	RP1 + NIVOLUMAB		Anti-PD-1 failed NMSC	No-Melanoma Skin Cancer	



ORL

STUDY NAME	PHASE	MOLECULE	COHORT TYPE			PREVIOUS LINE
			COHORT NUMBER	TUMOR TYPE	SPECIFICITY	
GS-US-548-5916	II	Magrolimab + pembrolizumab + platinum + 5-FU (Arm A) versus pembrolizumab + platinum + 5-FU (Arm B) versus a delayed open arm magrolimab + zimberelimab + platinum + 5-FU (Arm C)	Cohorte 1	Merkel Cell Carcinoma	squamous cell carcinoma of the head and neck	No prior line in metastatic stage

Tous ces essais sont à retrouver sur ACTIS Oncology sur l'application Oncoclic pour un adressage facilité de vos patients, télécharger l'application :



UROLOGY

Tous ces essais sont à retrouver sur ACTIS Oncology sur l'application Oncoclic pour un adressage facilité de vos patients, télécharger l'application :



STUDY NAME	PHASE	MOLECULE	COHORT TYPE			PREVIOUS LINE
			COHORT NUMBER	TUMOR TYPE	SPECIFICITY	
AGADIR	II	Atezolizumab + BDB001 + radiothérapie	5	UBC	Refractory anti PD-1/L1	
BI 1403-0002	Ib	BI 907828 avec le BI 754091 (ezabenlimab)	2C	Urothelial carcinoma	TP53 TS, MDM2 amplified	Patients with radiologically documented disease progression or relapse during or after
BT8009	II	BT8009 5 mg/m ²	B3	UROTHELIAL EV NAIVE		Recurred after or have been refractory to previous therapy
			B7	urothelial	Combo with pembrolizumab	First-line cisplatin-ineligible
EVICTION -ICT-01-101	I/Ila	ICT01 + Pembrolizumab	H	Bladder Chemotx failure	Circulating γ962 T cell count ≥ 20000 cells/mL Pembro Combo	At least one line
REGOMUNE	II	Regorafenib + Avelumab	J	Urothelial		At least one line and max 1 line of PD(L)1 mAb (received at least 4 month), anti PDL1 not mandatory
			O	Non clear-cell renal carcinoma		

GYNECOLOGY

STUDY NAME	PHASE	MOLECULE	COHORT TYPE			PREVIOUS LINE
			COHORT NUMBER	TUMOR TYPE	SPECIFICITY	
BT8009	II	BT8009	M3	Endometrial carcinoma	ARID1A mutant	Previous treatment with EZH2 inhibitor forbidden
INCIB123667-101	I	INCIB123667	Part 1b grp 2	endometrial/uterine cancer	CCNE1 amplification	3 prior lines of systemic therapy max



DIGESTIF

Tous ces essais sont à retrouver sur ACTIS Oncology sur l'application Oncoclic pour un adressage facilité de vos patients, télécharger l'application :



STUDY NAME	PHASE	MOLECULE	COHORT TYPE			PREVIOUS LINE
			COHORT NUMBER	TUMOR TYPE	SPECIFICITY	
BI 1403-0002	Ib	BI 907828 + BI 754091 (ezabenlimab)	2B	TP53 TS MDM2 amplified gastric carcinoma		Patients with radiologically documented disease progression or relapse during or after all standard of care treatments
			2D	TP53 TS MDM2 amplified bile duct carcinoma		Patients with radiologically documented disease progression or relapse during or after all standard of care treatments
CFT1946-1101	I/II	CFT1946	Arm A (CFT1946 monotherapy)	CRC	Systemic chemotherapy based regimen per SoC for unresectable locally advanced or metastatic disease, and a BRAFi in combination with an EGFR mAb. NOTE : Both MSS and MSI-H CRC are eligible for inclusion in this study, although required prior therapy differs (MSI-H requires prior immunotherapy)	Subjects with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) CRC must have received immunotherapy. Subjects with microsatellite stable (MSS) CRC are eligible, provided they have received at least 2 prior treatments.
KontRaSt-03	I/II	JDG444 + Cetuximab	3	CRC	Histologically confirmed advanced KRAS G12C mutant	Patients must have had fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy
LOXO-RAS-20001	Ib expansion	LY3537982	F1	Pancreas	KRASG12C Tumor tissue or liquid biopsy	Patient must have progressed/be intolerant/ineligible for immunotherapy and platinum based therapy No mutation : EGFR, ALK, BRAF (V600), MET (exon 14), ROS1, RET or NTRK 1/2/3
REGOMUNE	II	Regorafenib + Avelumab	A'	Colorectal	MSI-high or MMR deficient (macrophagique infiltrate)	At least one line
RLY 4008	I	RLY-4008	Part 2 grp 2A	intrahepatic cholangiocarcinoma	FGFR2-fusion	FGFR2-fusion ICC without prior FGFRi



SARCOMAS

Tous ces essais sont à retrouver sur ACTIS Oncology sur l'application Oncoclic pour un adressage facilité de vos patients, télécharger l'application :



STUDY NAME	PHASE	MOLECULE	COHORT TYPE			PREVIOUS LINE
			COHORT NUMBER	TUMOR TYPE	SPECIFICITY	
BI1403-0002	Ib	BI 907828 + BI 754091 (ezabenlimab)	1C	TP53 TS myxofibrosarcoma		Patients with radiologically documented disease progression or relapse during or after all standard of care treatments.
BT-001.01	II	Pembrolizumab IV + TG6030 IT	RDP2	STS		One prior line of systemic therapy
Multisarc	II	Olaparib-Durvalumab		STS	Unresectable, targetable alteration	At least one line for metastatic disease or locally advanced disease

NEUROLOGY

STUDY NAME	PHASE	MOLECULE	COHORT TYPE			PREVIOUS LINE
			COHORT NUMBER	TUMOR TYPE	SPECIFICITY	
MegaMOST	II	Alectinib BID	C	Neuroblastoma	Activating ALK alterations : translocation, mutation	At least one line for metastatic disease, no previous ALK inhibitor (except crizotinib)

Hematology

STUDY NAME	PHASE	MOLECULE	COHORT TYPE			PREVIOUS LINE
			COHORT NUMBER	TUMOR TYPE	SPECIFICITY	
EVICTION-ICT-01-101	I/Ila	ICT01	F	Acute myeloid leukemia		At least one line



Solid tumors

Tous ces essais sont à retrouver sur ACTIS Oncology sur l'application Oncoclic pour un adressage facilité de vos patients, télécharger l'application :



STUDY NAME	PHASE	MOLECULE	COHORT TYPE			PREVIOUS LINE
			COHORT NUMBER	TUMOR TYPE	SPECIFICITY	
BT8009	II	BT8009 5mg/m2	C	Solid Tumors	Reduced renal function of 30-49 mL/min	Recurred after or have been refractory to previous therapy
CA120-1001	I	BMS-986449	Part 1C	TNBC	regardless of PD-L1 status	Must not be a candidate for other approved therapeutic regimen
CFT1946-1101	I/II	CFT1946 + Tramétiñib	Arm B	Other [non-CNS] Solid tumors	including BRAFi if available and of benefit to the subject	With disease progression on or after last prior treatment
CO42800	I	Inavolisib	2	HNSCC	PI3KCA TUMOR TISSUE OR LIQUID BIOPSY	Must have received standard therapy
				Ovarian	PI3KCA TUMOR TISSUE OR LIQUID BIOPSY	Must have received standard therapy
ELVN-002-001	Ia/Ib	ELVN-002 +/- fam-trastuzumab deruxtecan-nxki (T-DXd) or ado-trastuzumab emtansine (T-DM1)	Dose escalation	Solid Tumors	HER2 mutation or HER2 amplification or HER2+(IHC3+ or IHC2+/ISH+), for NSCLC patients no EGFR, ROS1, ALK or BRAF V600E mutation	No limit
EVICTION-ICT-01-101	I/IIa	ICT01 + Pembrolizumab	I	HNSCC CPI-failures	Circulating γ 962 T cell count \geq 20000 cells/mL	At least one line
EZH-1201	I	Tazemetostat	1	Solid Tumors	Moderate hepatic impairment (NCI-ODWG)	At least one line, no prior anti-EZH2
			2	Solid Tumors	Severe hepatic impairment (NCI-ODWG)	At least one line, no prior anti-EZH2



Tous ces essais sont à retrouver sur ACTIS Oncology sur l'application Oncoclic pour un adressage facilité de vos patients, télécharger l'application :

Solid tumors

STUDY NAME	PHASE	MOLECULE	COHORT TYPE			PREVIOUS LINE
			COHORT NUMBER	TUMOR TYPE	SPECIFICITY	
GCT1042-02	I/II	RT+ GEN1042 +/- Pembrolizumab	Part1, cohort 1	Metastatic non-CNS solid tumors		At least 1 line and 3 lines maximum
IDE397-001	I	IDE397 Monotherapy	PART 2 dose expansion	Lung (squamous and adenocarcinoma)	homozygous loss of MTAP or MTAP deletion	at least 1 line and no more 3 prior lines (no more 2 prior lines of cytotoxic chemotherapy)
IGNYTE	II	RP1 + NIVOLUMAB		Solid Tumors	anti-PD1 failed MSI-H/dMMR	Prior therapy with an anti-PD1/-L1, anti-PD-L2
INCB123667-101	I	INCB123667	Part 1a	advanced or metastatic solid tumors	CCNE1 amplification	
LOXO RET 17001 LIBRETTO 001	I	Sepelcatinib	1	Solid tumors (other than NSCLC and MTC)	RET-fusion-positive	Progressed on or intolerant to ≥ 1 prior standard first-line therapy
			2	Solid tumors (other than NSCLC and MTC)	RET-fusion-positive	No prior standard first-line therapy
			5	Cohorts 1 to 4 tumors	Without measurable disease	



Solid tumors

Tous ces essais sont à retrouver sur ACTIS Oncology sur l'application Oncoclic pour un adressage facilité de vos patients, télécharger l'application :



STUDY NAME	PHASE	MOLECULE	COHORT TYPE			PREVIOUS LINE
			COHORT NUMBER	TUMOR TYPE	SPECIFICITY	
MegaMOST	II	Cabozantinib QD	B	Solid Tumors	AXL, MET, VEGFR, VEGF, RET, ROS1, MER, TRKB, TIE-2 and/or Tyro3 activating mutations/amplification, and/or NTRK translocation TUMOR TISSUE OR LIQUID BIOPSY	At least one line for metastatic disease
		Alectinib BID	C	Solid Tumors	Activating ALK alterations : translocation, mutation	At least one line for metastatic disease, no previous ALK inhibitor (except crizotinib)
		Regorafenib 3 weeks on / 1 week off	D	Solid Tumors	Activating mutation and/or amplification of VEGFR1-3, TIE-2, KIT, RET, RAF1, BRAF (other than V600 mutations), CRAF, HRAS, KRAS, PDGFR, FGFR1-2, FLT3 and/or CSFR1 ; amplification of the ligands ; biallelic inactivation of SMAD4 TUMOR TISSUE OR LIQUID BIOPSY	At least one line for metastatic disease
		Trametinib QD	E	Solid Tumors	Activating mutation and/or amplification of KRAS (sauf KRAS G12), NRAS, HRAS and/or MAP2K ; biallelic inactivation of NF1 ; activating mutation of PTPN11 ; amplification or translocation of BRAF TUMOR TISSUE OR LIQUID BIOPSY Except melanoma, lung with KRAS G12C mutation, CRC and PDAC with KRAS mutations	At least one line for metastatic disease
		Trametinib QD + Dabrafenib BID	F	Solid Tumors	BRAF V600 mutation, tumor tissue or liquid biopsy Except melanoma, lung and CRC	At least one line for metastatic disease



Solid tumors

Tous ces essais sont à retrouver sur ACTIS Oncology sur l'application Oncoclic pour un adressage facilité de vos patients, télécharger l'application :



STUDY NAME	PHASE	MOLECULE	COHORT TYPE			PREVIOUS LINE
			COHORT NUMBER	TUMOR TYPE	SPECIFICITY	
MK-7339-002	II	Olaparib	3	Solid tumors	HRD positif Except ovarian and sarcoma	At least one line and max 2 lines, platine-sensitive if applicable
MOST PLUS	II	Nilotinib		PVNS	ABL1, KIT, PDGFRA, PDGFRB, DDR1, DDR2, CSF1R mutations	At least one line
		Durvalumab + Tremelimumab		Solid tumors	Immunogenic, MSI high Except lung, head, neck and CNS cancer	At least one line and max 2 lines
PEMBIB	Ib	Nintedanib + Pembrolizumab		Solid Tumors TMB-high	Naïf anti-PDL1/PD-1	At least one line
REGOMUNE	II	Regorafenib + Avelumab	K	Solid tumors	P16+	At least one line and max 1 line of PD(L)1 mAb (received at least 4 month) anti PDL1 not mandatory
			M	Solid tumors	TMB-H (>16 mut/mgb on tissue or blood sample)	At least one line and max 1 line of PD(L)1 mAb (received at least 4 month) anti PDL1 not mandatory
			N	Solid tumors	MSI-H	At least one line, anti PDL1 not mandatory
RLY 4008	I	RLY 4008	Part 2 group 3	non intrahepatic cholangiocarcinoma	FGFR2-fusion+	FGFR2-fusion+ non ICC with/without prior FGFR1
			Part 2 group 4	Advanced solid tumors	FGFR2-amplified	FGFR2-amplified, advanced solid tumors with/without prior FGFR1
TAPISTRY	II	ENTRECTINIB	A	Solid tumors	ROS1 fusion-positive (except NSCLC) TUMOR TISSUE OR LIQUID (VALIDATION NEEDED)	
		ENTRECTINIB	B	Solid tumors	NTRK1/2/3 fusion-positive TUMOR TISSUE OR LIQUID (VALIDATION NEEDED)	
		ALECTINIB	C	Solid tumors	ALK fusion-positive (except NSCLC) TUMOR TISSUE OR LIQUID (VALIDATION NEEDED)	
		Pralsetinib	K	Solid tumors	Fusion Ret (TUMOR TISSUE OR LIQUID VALIDATION NEEDED)	
TAS-120-202	II	Futibatinib	A	Solid tumors	FGFR1-4 rearrangement Except primary brain tumor or intrahepatic cholangiocarcinoma TUMOR TISSUE	Standard treatment

